Collegium Pharmaceutical Inc. is a specialty pharmaceutical company. It develops and commercializes prescription and over-the-counter pharmaceuticals for the treatment of central nervous system, respiratory and skin related disorders. The Company's product candidate consists of COL-195, COL-196, COL-171, COL-003 and COL-172 which are in different clinical trial. It developed a formulation platform technology, DETERx, for the treatment of chronic pain. Collegium Pharmaceutical Inc. is based in CUMBERLAND, United States....
+See MoreSharpe-Lintner-Black CAPM alpha (Premium Members Only) Fama-French (1993) 3-factor alpha (Premium Members Only) Fama-French-Carhart 4-factor alpha (Premium Members Only) Fama-French (2015) 5-factor alpha (Premium Members Only) Fama-French-Carhart 6-factor alpha (Premium Members Only) Dynamic conditional 6-factor alpha (Premium Members Only) Last update: Saturday 11 July 2026
2018-07-07 10:33:00 Saturday ET

The east-west tech rivalry intensifies between BATs (Baidu, Alibaba, and Tencent) and FAANGs (Facebook, Apple, Amazon, Netflix, and Google). These Sino-U.S.
2025-10-02 12:31:00 Thursday ET

Stock Synopsis: With a new Python program, we use, adapt, apply, and leverage each of the mainstream Gemini Gen AI models to conduct this comprehensive fund
2016-11-09 00:00:00 Wednesday ET

Universally dismissed as a vanity presidential candidate when he entered a field crowded with Republican talent, the former Democrat and former Independent
2019-10-23 15:39:00 Wednesday ET

American CEOs of about 200 corporations issue a joint statement in support of stakeholder value maximization. The Business Roundtable offers this statement
2023-10-07 10:24:00 Saturday ET

Thomas Philippon draws attention to greater antitrust scrutiny in light of the rise of market power and its economic ripple effects. Thomas Philippon (20
2019-09-11 09:31:00 Wednesday ET

Central banks in India, Thailand, and New Zealand lower their interest rates in a defensive response to the Federal Reserve recent rate cut. The central ban